• Wondering if Merit Medical Systems at US$63.06 is priced attractively or if risk is being misread by the market? This article breaks down what the current valuation metrics are really saying about the stock.
• The share price has slipped about 1.7% over the past week and is up 1.7% over the past month, while the year-to-date return is down 27.1% and the one-year return is down 33.6%. The three-year return is down 25.2% and the five-year return is up 4.4%.
• Recent coverage has focused on how the stock's weaker one-year and year-to-date performance compares to its longer-term five-year return, prompting questions about whether expectations around the business have reset. This has put more attention on whether the current price properly reflects the fundamentals and long-term prospects.
• On Simply Wall St's 6 point valuation checklist, Merit Medical Systems scores a 3, with the stock assessed as undervalued on 3 out of 6 measures. The next sections will walk through different valuation approaches before finishing with an even broader way to think about what "fair value" really means for this company.

Approach 1: Merit Medical Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash it may generate in the future and then discounting those cash flows back to today.

For Merit Medical Systems, the model used is a 2 Stage Free Cash Flow to Equity approach, based on the company’s latest twelve month Free Cash Flow of about $237.7 million. Analysts provide detailed Free Cash Flow estimates out to 2028, with Simply Wall St extending these further using its own extrapolations. By 2035, the projected Free Cash Flow in this model is $348.8 million, all expressed in $ and discounted back to today using the model’s required return assumptions.

Putting those projections together, the DCF model arrives at an estimated intrinsic value of $95.20 per share. Versus the recent share price of $63.06, that implies the stock trades at roughly a 33.8% discount to this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems is undervalued by 33.8%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Merit Medical Systems Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it ties the share price directly to the earnings that support it. A higher or lower P/E often reflects what the market is willing to pay for each dollar of profit, given expectations and perceived risk.

Growth expectations and risk usually shape what looks like a “normal” or “fair” P/E. Higher expected earnings growth or more predictable results can support a higher multiple, while lower growth or higher perceived risk typically point to a lower one.

Merit Medical Systems currently trades on a P/E of 27.0x. This is above the Medical Equipment industry average of about 24.2x and below the peer group average of 38.2x. Simply Wall St’s “Fair Ratio” for Merit Medical Systems is 21.8x. This proprietary metric estimates a P/E that would be reasonable given factors such as the company’s earnings growth profile, profit margins, industry, market cap and key risks.

Because the Fair Ratio is tailored to the company’s own characteristics, it offers a more focused reference point than broad peer or industry comparisons. With the current P/E of 27.0x above the Fair Ratio of 21.8x, the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Merit Medical Systems Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in as a simple way for you to attach a clear story to the numbers you are seeing on Merit Medical Systems.

A Narrative is your structured view of the company, where you set out what you think is happening in the business, link that to specific assumptions for future revenue, earnings and margins, and then see what those assumptions imply for fair value.

On Simply Wall St’s Community page, millions of investors use Narratives as an easy tool to connect a company’s story to a financial forecast, compare the resulting Fair Value to today’s share price and then decide whether the stock looks expensive or cheap based on their own view rather than a single model.

Narratives update automatically when new information such as news, recalls or earnings guidance is added, so your fair value view can adjust without you rebuilding a spreadsheet every time something changes.

For Merit Medical Systems, one bullish Narrative on the platform currently translates into a Fair Value of about US$118.22 while a more cautious Narrative points to about US$74.00. By exploring both side by side you can quickly see how different assumptions about oncology and endoscopy growth, margins, tariffs and OEM demand lead to very different views of what the stock is worth.

Do you think there's more to the story for Merit Medical Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.